AN2 Therapeutics, Inc. (ANTX)
| Market Cap | 609.40M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -59.68M |
| Shares Out | 29.74M |
| EPS (ttm) | -2.83 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 113,305 |
| Open | 20.78 |
| Previous Close | 20.90 |
| Day's Range | 20.26 - 21.33 |
| 52-Week Range | 4.87 - 21.70 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 24.00 (+17.13%) |
| Earnings Date | Nov 9, 2023 |
About ANTX
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, which is in a pivotal Phase 2/3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California. [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for ANTX stock is "Buy" and the 12-month stock price forecast is $24.0.
News
AN2 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business and Scientific Highlights
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseas...
AN2 Therapeutics to Present at Upcoming Investor Conferences
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseas...
AN2 Therapeutics Signs License Agreement with the University of Georgia Research Foundation to Develop Novel Boron-Based Therapy for Chagas Disease
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseas...
AN2 Therapeutics to Present New Data for Epetraborole at IDWeek 2023
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseas...
AN2 Therapeutics Signs Grant Agreement to Discover Novel, Boron Based Therapies for Tuberculosis and Malaria
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseas...
AN2 Therapeutics commences Phase 3 Part of Phase 2/3 Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium complex (MAC) Lung Disease
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseas...
AN2 Therapeutics Announces Pricing of $70.0 Million Underwritten Offering of Common Stock
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseas...
AN2 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseas...
AN2 Therapeutics to Present at Jefferies Healthcare Conference
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseas...
AN2 Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseas...
AN2 Therapeutics to Present at JMP Securities Life Sciences Conference
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseas...
AN2 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseas...
AN2 Therapeutics to Participate in Upcoming Investor Conferences
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseas...
AN2 Therapeutics to Present at SVB Securities Global Biopharma Conference
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious dise...
AN2 Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates
MENLO PARK, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious ...
AN2 Therapeutics to Present New Epetraborole Data at IDWeek 2022
MENLO PARK, Calif., Oct. 19, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious ...
AN2 Therapeutics Provides Update on Epetraborole Ex-U.S. Development Plan in Treatment-Refractory MAC Lung Disease
MENLO PARK, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious ...
NIH Awards Contract to AN2 Therapeutics Valued Up to $17.8 Million
NIAID Agreement to Advance Development of Epetraborole for Acute Systemic Melioidosis NIAID Agreement to Advance Development of Epetraborole for Acute Systemic Melioidosis
AN2 Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference
MENLO PARK, Calif., Aug. 29, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious ...
AN2 Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates
MENLO PARK, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious...
AN2 Therapeutics Initiates Pivotal Phase 2/3 Trial Evaluating Epetraborole for Treatment-Refractory MAC Lung Disease
MENLO PARK, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious ...
AN2 Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates
MENLO PARK, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious i...
AN2 Therapeutics Appoints Maggie FitzPatrick to Its Board of Directors
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc., (NASDAQ: ANTX) a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with hig...
RA Capital-Backed AN2 Therapeutics Hits NASDAQ, With IPO Price At $15
AN2 Therapeutics Inc (NASDAQ: ANTX) will be offering 4.6 million shares at $15 a share in its initial public offering, under the ticker 'ANTX,' raising $69 million. The Company announced IPO plans ea...
AN2 Therapeutics Stock to List Today
Biotech AN2 Therapeutics sold 4.6 million shares at $15 each, the mid-point of its $14 to $16 range. It's the second conventional IPO this month.